Velcade

(bortezomib)

ApprovedSmall molecule

Bortezomib is used to treat certain types of cancer, including multiple myeloma (a blood cancer) and mantle cell lymphoma. It works by blocking proteins that help cancer cells survive and grow.[2] Velcade is currently approved and in use across 57 indications[4].[1]

Velcade is one of 876 small molecule programs targeting Pancreatic Cancer. It is currently in Approved.

Indications

752

Total Trials

Active Trials

875

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Pancreatic CancerRecruiting

Multiple MyelomaCompleted

LymphomaUnknown status

Acute Lymphoblastic LeukemiaRecruiting

TreatmentRecruiting

Other Solid TumorsCompleted

DexamethasoneCompleted

Newly DiagnosedCompleted

Peripheral Blood Stem Cell TransplantationCompleted

Gastric CancerApproved

Pancreatic CancerPhase 2

Recruiting

Multiple MyelomaApproved

Completed

LymphomaPhase 3

Unknown status

Acute Lymphoblastic LeukemiaPhase 3

Recruiting

TreatmentPhase 2

Recruiting

Other Solid TumorsPhase 1

Completed

DexamethasonePhase 3

Completed

Newly DiagnosedPhase 3

Completed

Peripheral Blood Stem Cell TransplantationPhase 2

Completed

Gastric CancerApproved

Approved

Showing 10 of 57 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Velcade

SShilpa Grover, MD, MPH

Approved

4 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Other Solid Tumors

NCT00479128

Q4 2026

Phase 2Recruiting

Plasmacytoma

NCT05248633

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT03989414

Phase 3Active, not recruiting

Dexamethasone

NCT01208662

Phase 2Recruiting

Chemotherapy

NCT04268199

Phase 3Active, not recruiting

Multiple Myeloma

NCT03729804

Clinical

Trials by Indication[1]

Multiple Myeloma74 trials

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Completed·MMayo Clinic·Phase 2·NCT01706666·3 enrolled

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Completed· Novartis logo

Novartis·Phase 1/2·NCT00708292·29 enrolled

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02874742·224 enrolled

Show 71 more trials

Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 1·NCT02220608·10 enrolled

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Completed·—·Phase 1·NCT02481934·5 enrolled

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1·NCT00153933·58 enrolled

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00560352·16 enrolled

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01497093·34 enrolled

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 4·NCT00652041·40 enrolled

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Withdrawn·UUniversity of Pittsburgh·Phase 2·NCT01329289

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated·WWashington University School of Medicine·Phase 1·NCT04912427·1 enrolled

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT00483262·63 enrolled

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

Unknown status·—··NCT04678089·350 enrolled

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02555839·127 enrolled

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Terminated·AAB Science·Phase 3·NCT01470131·147 enrolled

Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study

Unknown status·YYonsei University·Phase 1/2·NCT01255527·53 enrolled

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·—·Phase 1·NCT00568880·25 enrolled

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01919086·30 enrolled

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00416273·217 enrolled

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00908232·163 enrolled

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

Completed·AAEterna Zentaris·Phase 1/2·NCT00401011·84 enrolled

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT01605032·19 enrolled

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00148317·38 enrolled

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03652064·395 enrolled

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT02037256·23 enrolled

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Completed·MMargarida Magalhaes-Silverman·Phase 2·NCT01849783·41 enrolled

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 3·NCT04246047·494 enrolled

Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

Completed·NNantes University Hospital·Phase 1·NCT00291538·20 enrolled

Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02811978·81 enrolled

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03989414·424 enrolled

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Withdrawn·UUniversity of Arkansas·Phase 2·NCT03168100

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00744354·32 enrolled

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Miami·Phase 2·NCT04268498·310 enrolled

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075881·44 enrolled

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01359657·46 enrolled

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Unknown status·HHellenic Society of Hematology·Phase 2·NCT05147493·51 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Active, not recruiting·UUniversity of Chicago·Phase 3·NCT03729804·250 enrolled

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT01936090·11 enrolled

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Completed· Roche logo

Roche·Phase 2·NCT00473590·102 enrolled

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05572515·614 enrolled

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00546780·31 enrolled

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 3·NCT04484623·302 enrolled

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT00752518·35 enrolled

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00773747·637 enrolled

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT03319667·475 enrolled

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1·NCT01965353·21 enrolled

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·UUniversity of Arkansas·Phase 2·NCT01062230·6 enrolled

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Completed·CCancer Trials Ireland·Phase 2·NCT02219178·42 enrolled

Panobinostat/Velcade in Multiple Myeloma

Terminated·UUniversity of Arkansas·Phase 1·NCT00891033·12 enrolled

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 3·NCT01146834·47 enrolled

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00103506·646 enrolled

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed·Ppharmaand GmbH·Phase 2·NCT02654990·248 enrolled

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

Withdrawn·—·Phase 4·NCT04348006

An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00431769·130 enrolled

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02224729·24 enrolled

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00858234·9 enrolled

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Completed· Novartis logo

Novartis·Phase 1·NCT01428492·90 enrolled

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Completed·PPharmaMar·Phase 1·NCT02100657·39 enrolled

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04570631·4 enrolled

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Completed·KKaryopharm Therapeutics Inc·Phase 3·NCT03110562·402 enrolled

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00833560·401 enrolled

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

Completed·VVejle Hospital·Phase 2·NCT01481194·35 enrolled

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03763162·40 enrolled

Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

Unknown status·YYongping Zhai·Phase 2·NCT02086942·94 enrolled

Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy

Completed·UUniversity of Athens·Phase 2·NCT00972959·17 enrolled

Bortezomib With Melphalan and Prednisone for Multiple Myeloma

Completed·—·Phase 2·NCT00734149·45 enrolled

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Recruiting·PPETHEMA Foundation·Phase 2·NCT07045909·30 enrolled

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Completed· Pfizer logo

Pfizer·Phase 2·NCT00555906·53 enrolled

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT02718833·52 enrolled

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT04414475·127 enrolled

Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1·NCT00080405·40 enrolled

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Completed·—·Phase 1·NCT01163357·18 enrolled

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193557·40 enrolled

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT03589222·62 enrolled

Lymphoma14 trials

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00810576·1 enrolled

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00992446·27 enrolled

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00217503·15 enrolled

Show 11 more trials

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated·UUniversity of Virginia·Phase 2·NCT00265928·46 enrolled

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00439361·14 enrolled

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00295932·79 enrolled

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02613598·15 enrolled

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00334438·12 enrolled

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Completed·PPierluigi Porcu·Phase 1·NCT01129180·8 enrolled

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01029730·55 enrolled

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00348985·55 enrolled

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Terminated·LLymphoma Study Association·Phase 2·NCT00136591·87 enrolled

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00994500·20 enrolled

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02783625·114 enrolled

Mantle Cell Lymphoma7 trials

Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00553644·53 enrolled

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Completed·GGemin X·Phase 1/2·NCT00407303·24 enrolled

Show 4 more trials

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05564052·36 enrolled

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Completed·—·Phase 2·NCT01267812·23 enrolled

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00633594·39 enrolled

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00581776·30 enrolled

Amyloidosis6 trials

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00520767·35 enrolled

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03201965·416 enrolled

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Completed·SStichting European Myeloma Network·Phase 2·NCT04131309·40 enrolled

Show 3 more trials

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01078454·11 enrolled

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07388602·90 enrolled

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04474938·40 enrolled

Macroglobulinemia5 trials

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00492050·46 enrolled

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1/2·NCT01125293·46 enrolled

Study of VTD in Waldenstrom's Macroglobulinemia

Unknown status·SSeoul National University Hospital·Phase 2·NCT03335098·15 enrolled

Show 2 more trials

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Completed·—·Phase 2·NCT00422799·63 enrolled

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00142129·27 enrolled

73 more indications

MALT lymphoma3 trials

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Terminated·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT00210392·12 enrolled

Velcade in MALT Lymphoma Patients

Completed·MMedical University of Vienna·Phase 2·NCT00373906·16 enrolled

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT00210327·33 enrolled

Acute Myeloid Leukemia3 trials

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01371981·1,645 enrolled

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00666588·52 enrolled

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01465386·6 enrolled

Thyroid Cancer2 trials

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00923247·22 enrolled

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00104871·24 enrolled

Patients With Advanced Solid Tumors2 trials

Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors

Completed·UUniversity of California, Davis·Phase 1·NCT00388089·24 enrolled

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00027898·27 enrolled

Newly Diagnosed2 trials

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Active, not recruiting·UUniversity of Heidelberg Medical Center·Phase 3·NCT03617731·662 enrolled

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting·IIda Bruun Kristensen·Phase 2·NCT04717700·50 enrolled

Dexamethasone2 trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Active, not recruiting·—·Phase 3·NCT01208662·729 enrolled

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Active, not recruiting·—·Phase 2·NCT04653246·52 enrolled

Refractory2 trials

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Completed·NNordic Myeloma Study Group·Phase 3·NCT00602511·300 enrolled

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT02542111·30 enrolled

Breast Cancer2 trials

PS-341 in Treating Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025584·35 enrolled

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Recruiting·SSun Yat-sen University·Phase 1·NCT06900647·20 enrolled

Non-Small Cell Lung Cancer2 trials

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01833143·17 enrolled

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT01633645·53 enrolled

Chronic Myelogenous Leukemia2 trials

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00383474·35 enrolled

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00023881·7 enrolled

Graft Versus Host Disease2 trials

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT00408928·11 enrolled

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Completed·—·Phase 1/2·NCT00369226·45 enrolled

Follicular Lymphoma2 trials

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01902862·7 enrolled

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

Completed·GGruppo Italiano Studio Linfomi·Phase 2·NCT01830465·45 enrolled

Acute Lymphoblastic Leukemia2 trials

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Completed·—·Phase 2·NCT04224571·208 enrolled

Treatment2 trials

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02719613·67 enrolled

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01910987·80 enrolled

Head and Neck Cancer2 trials

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445405·3 enrolled

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00629226·46 enrolled

Trial2 trials

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Completed·NNorthwestern University·Phase 2·NCT00369707·42 enrolled

Bortezomib Consolidation Trial

Completed·UUniversity College, London·Phase 2·NCT01517724·40 enrolled

Gastroesophageal Junction2 trials

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00107341·37 enrolled

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00061932·41 enrolled

CHOP1 trial

Ph II CHOP+Velcade in Mediastinal LBCL

Terminated·—·Phase 2·NCT00361621·3 enrolled

Stage IV Rectal Cancer1 trial

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00280176·11 enrolled

Metastatic Colorectal Cancer1 trial

Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00098982·16 enrolled

Fallopian Tube Cancer1 trial

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01074411·33 enrolled

Toxicity1 trial

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Terminated·EEmory University·Phase 2·NCT02877082·5 enrolled

Myelodysplasia1 trial

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Completed·MMassachusetts General Hospital·Phase 1·NCT00580242·23 enrolled

Hematopoietic Stem Cell Transplant1 trial

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Completed·—·Phase 2·NCT01754389·138 enrolled

Daratumumab1 trial

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Terminated·OOncopeptides AB·Phase 1/2·NCT03481556·56 enrolled

Intrahepatic Cholangiocellular Carcinoma1 trial

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Unknown status·ZZhengang Yuan·Phase 3·NCT03345303·50 enrolled

Desensitization1 trial

Desensitization With Bortezomib Before a Living Kidney Donation

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01842074·10 enrolled

Advanced Stage1 trial

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Completed· Novartis logo

Novartis·Phase 2·NCT01337752·9 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00851552·9 enrolled

Kidney Transplant1 trial

Bortezomib in Rejection of Kidney Transplants

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02201576·60 enrolled

Autologous Stem Cell Transplantation1 trial

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 2·NCT01653418·10 enrolled

Relapsed or Refractory1 trial

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00103272·74 enrolled

Stem Cell Transplant1 trial

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00307086·30 enrolled

Advanced Malignancy1 trial

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00428545·104 enrolled

Maintenance Therapy1 trial

2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

Withdrawn·UUniversity of Arkansas·Phase 2·NCT03000634

Recurrent Ovarian Epithelial Cancer1 trial

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00023712·58 enrolled

Waldenstrom macroglobulinemia1 trial

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00723658

Ovarian Cancer1 trial

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Withdrawn· Takeda logo

Takeda·Phase 2·NCT00610792·91 enrolled

Chronic Lymphocytic Leukemia1 trial

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed· Gilead logo

Gilead·Phase 1·NCT01088048·241 enrolled

Observational Study1 trial

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00440479·11 enrolled

IgA Nephropathy1 trial

Pilot Study of Velcade® in IgA Nephropathy

Completed·TThe Rogosin Institute·Phase 4·NCT01103778·11 enrolled

Lenalidomide1 trial

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed·PPETHEMA Foundation·Phase 3·NCT01916252·460 enrolled

AL amyloidosis1 trial

Rapid dFLC Response Predict CHR in AL Amyloidosis

Recruiting·PPeking University People's Hospital··NCT06627309·50 enrolled

HSCT1 trial

Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients

Completed·TTing YANG··NCT07200583·50 enrolled

Intravenous1 trial

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00059631·42 enrolled

AIN1 trial

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Terminated·OOncotherapeutics·Phase 2·NCT01695330·5 enrolled

Plasmacytoma1 trial

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05248633·220 enrolled

First-line Treatment1 trial

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT05135442·30 enrolled

Chemotherapy1 trial

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT04268199·100 enrolled

ITP1 trial

Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

Unknown status·SShandong University·Phase 3·NCT03443570·200 enrolled

MDS1 trial

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Completed·—·N/A·NCT00789256·26 enrolled

Colorectal Cancer1 trial

Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00052507

Brain Tumors1 trial

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00108069·43 enrolled

Other Solid Tumors1 trial

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT00479128·80 enrolled

Autoimmune Encephalitis1 trial

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

Recruiting·JJena University Hospital·Phase 2·NCT03993262·50 enrolled

Unresectable Solid Tumor1 trial

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00227513·66 enrolled

Metastatic Melanoma1 trial

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00288041·36 enrolled

Malignant Glioma1 trial

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

Completed·—·Phase 2·NCT00611325·56 enrolled

Lung Cancer1 trial

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00118144·42 enrolled

TED1 trial

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Completed· Takeda logo

Takeda·Phase 1·NCT00129207

Hematologic Malignancies1 trial

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02352558·15 enrolled

Immunodeficiency1 trial

Treatment of Adult-Onset Immunodeficiency With Bortezomib

Unknown status·MMahidol University·Phase 2·NCT03103555·5 enrolled

Advanced Solid Tumors1 trial

Bortezomib in Treating Children With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00021216·36 enrolled

Bone1 trial

Velcade Consolidation Bone Study

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01286077·106 enrolled

Melanoma1 trial

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00024011·50 enrolled

Transplantation1 trial

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Terminated·UUniversity of Iowa·Phase 2·NCT01548573·19 enrolled

Autoimmune Disease1 trial

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

Terminated·—·Phase 2·NCT02102594·11 enrolled

Rheumatoid Arthritis1 trial

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Unknown status·PPeking Union Medical College Hospital·N/A·NCT06215638·30 enrolled

Unspecified3 trials

Study of Erlotinib in Combination With Bortezomib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00895687·24 enrolled

PAD. ICORG 05-01, V11

Completed·CCancer Trials Ireland·Phase 2·NCT00814541·53 enrolled

Velcade (Bortezomib) Consolidation After Transplant

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01539083·256 enrolled

Regulatory

FDA Approval Timeline[5]

May 13, 2003

VELCADE

NDA NDA021602

May 13, 2003

VELCADE

NDA NDA021602

May 25, 2004

VELCADE

NDA NDA021602

Mar 25, 2005

VELCADE

NDA NDA021602

Dec 8, 2005

VELCADE

NDA NDA021602

May 31, 2006

VELCADE

NDA NDA021602

Dec 8, 2006

VELCADE

NDA NDA021602

Oct 10, 2007

VELCADE

NDA NDA021602

Jun 20, 2008

VELCADE

NDA NDA021602

Apr 24, 2009

VELCADE

NDA NDA021602

Dec 30, 2009

VELCADE

NDA NDA021602

Dec 30, 2009

VELCADE

NDA NDA021602

Dec 3, 2010

VELCADE

NDA NDA021602

Apr 7, 2011

VELCADE

NDA NDA021602

Nov 1, 2011

VELCADE

NDA NDA021602

Nov 1, 2011

VELCADE

NDA NDA021602

Jan 23, 2012

VELCADE

NDA NDA021602

Oct 26, 2012

VELCADE

NDA NDA021602

Oct 26, 2012

VELCADE

NDA NDA021602

Apr 1, 2013

VELCADE

NDA NDA021602

Aug 2, 2013

VELCADE

NDA NDA021602

Aug 5, 2013

VELCADE

NDA NDA021602

Mar 13, 2014

VELCADE

NDA NDA021602

Aug 8, 2014

VELCADE

NDA NDA021602

Sep 8, 2014

VELCADE

NDA NDA021602

Oct 8, 2014

VELCADE

NDA NDA021602

Aug 20, 2015

VELCADE

NDA NDA021602

Sep 14, 2015

VELCADE

NDA NDA021602

Jun 9, 2017

VELCADE

NDA NDA021602

Nov 6, 2017

BORTEZOMIB

NDA NDA205004

Apr 25, 2019

VELCADE

NDA NDA021602

Oct 4, 2019

BORTEZOMIB

NDA NDA206927

Oct 25, 2021

VELCADE

NDA NDA021602

Nov 4, 2021

VELCADE

NDA NDA021602

May 2, 2022

BORTEZOMIB

NDA NDA209191

Jul 26, 2022

BORTEZOMIB

NDA NDA215441

Jul 27, 2022

BORTEZOMIB

NDA NDA215331

Aug 26, 2024

BORTEZOMIB

NDA NDA212782

Sources

References

[1]
ClinicalTrials.gov — 752 trial records for bortezomib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Velcade drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — bortezomib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for bortezomib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA212782). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Velcade. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Shilpa Grover, MD, MPH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SShilpa Grover, MD, MPH

Patent Landscape[6]

Patent Cliff

Nov 3, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8962572Nov 3, 2032

11752164Sep 23, 2042

11679119Sep 23, 2042

12005069Sep 23, 2042

Velcade

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Multiple Myeloma74 trials

Lymphoma14 trials

Mantle Cell Lymphoma7 trials

Amyloidosis6 trials

Macroglobulinemia5 trials

MALT lymphoma3 trials

Acute Myeloid Leukemia3 trials

Thyroid Cancer2 trials

Patients With Advanced Solid Tumors2 trials

Newly Diagnosed2 trials

Dexamethasone2 trials

Refractory2 trials

Breast Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Chronic Myelogenous Leukemia2 trials

Graft Versus Host Disease2 trials

Follicular Lymphoma2 trials

Acute Lymphoblastic Leukemia2 trials

Treatment2 trials

Head and Neck Cancer2 trials

Trial2 trials

Gastroesophageal Junction2 trials

CHOP1 trial

Stage IV Rectal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Fallopian Tube Cancer1 trial

Toxicity1 trial

Myelodysplasia1 trial

Hematopoietic Stem Cell Transplant1 trial

Daratumumab1 trial

Intrahepatic Cholangiocellular Carcinoma1 trial

Desensitization1 trial

Advanced Stage1 trial

Malignant Solid Tumors1 trial

Malignant Mesothelioma1 trial

Metastatic Neuroendocrine Tumor1 trial

Renal insufficiency1 trial

Diffuse Large B-Cell Lymphoma1 trial

Kidney Transplant1 trial

Autologous Stem Cell Transplantation1 trial

Relapsed or Refractory1 trial

Stem Cell Transplant1 trial

Advanced Malignancy1 trial

Maintenance Therapy1 trial

Recurrent Ovarian Epithelial Cancer1 trial

Waldenstrom macroglobulinemia1 trial

Ovarian Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Observational Study1 trial

IgA Nephropathy1 trial

Lenalidomide1 trial

AL amyloidosis1 trial

HSCT1 trial

Intravenous1 trial

AIN1 trial

Plasmacytoma1 trial

First-line Treatment1 trial

Chemotherapy1 trial

ITP1 trial

MDS1 trial

Colorectal Cancer1 trial

Brain Tumors1 trial

Other Solid Tumors1 trial

Autoimmune Encephalitis1 trial

Unresectable Solid Tumor1 trial

Metastatic Melanoma1 trial

Malignant Glioma1 trial

Lung Cancer1 trial

TED1 trial

Hematologic Malignancies1 trial

Immunodeficiency1 trial

Advanced Solid Tumors1 trial

Bone1 trial